Generic Name: islatravir
Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Company: Merck & Company
Approval Status: Experimental
Generic Version Available: No
Experimental Code: MK-8591
Drug Indication
Islatravir is an investigational drug being studied to treat and prevent HIV. It has not yet been approved by the Food and Drug Administration or reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.
General Info
Islatravir belongs to a group of HIV drugs called nucleoside reverse transcriptase translocation inhibitors. It may be effective against certain HIV strains that are resistant to other drugs.
Islatravir is currently in Phase III development for HIV treatment. It is being studied as a single-drug capsule and as part of a fixed-dose combination containing doravirine and islatravir. It is also being studied as part of a once-weekly treatment regimen with another experimental drug.
Oral islatravir is also being studied as a once-monthly pre-exposure prophylaxis (PrEP) option. In implantable formulation of the drug may prevent HIV for as long as a year.
Dosage
Dosing Info: N/A
Side Effects
In clinical trials, the most commonly reported side effects among participants who took islatravir were headache, nausea, vomiting, diarrhea and joint pain.
Other Info
Click here for more info on Islatravir.
Last Reviewed: December 30, 2020
